Nabla, a leading provider of AI assistants for clinical care, has announced the appointment of Brian Manning as its new Chief Executive Officer. This strategic move positions the Boston-based executive, with over two decades of experience in scaling health-tech businesses, to lead Nabla's next phase of growth. Co-founder Alexandre Lebrun will transition to the role of Executive Chairman and Chief AI Officer, continuing to guide the company's technological vision.
Strategic Leadership for a New Era of AI
Alexandre Lebrun's transition allows him to deepen his focus on Nabla's long-term AI strategy while also serving as CEO of AMI Labs, a frontier AI research firm founded by Yann LeCun. Lebrun will remain deeply involved with Nabla, retaining his positions as Executive Chairman and Chief AI Officer. This leadership structure ensures continuity in innovation while bringing in new commercial expertise to steer the company's expansion.
The appointment follows months of anticipation after Lebrun took the helm at AMI Labs, which recently secured over a billion dollars in funding. Nabla benefits from an exclusive partnership with AMI Labs, gaining early access to breakthrough research, including emerging world models. This collaboration is set to shape the future of clinical intelligence, providing Nabla with a distinct competitive advantage in the market.
An Experienced Leader to Drive Commercial Growth
Brian Manning brings a wealth of experience from his time at prominent health-tech companies like Bamboo Health, PatientPing, and Zocdoc. Most recently, he served as President and Chief Revenue Officer at Bamboo Health, where he was instrumental in scaling the company to over $140 million in annual recurring revenue. His proven ability to build high-performing commercial teams is a key asset for Nabla's ambitious goals.
Manning's expertise in building go-to-market organizations from the ground up is particularly relevant as Nabla seeks to accelerate its enterprise growth. He expressed his attraction to Nabla's strong team, mission, and product excellence, highlighting the opportunity to build on its established trust with clinicians. His leadership is expected to expand Nabla's reach and solidify its position as a preferred clinical AI partner.
Capitalizing on Significant Market Traction
The leadership change comes as Nabla enjoys significant commercial momentum, with its platform supporting over 190 healthcare organizations and 100,000 clinicians. The company's AI assistant is deployed across major health systems, including CVS Health, UCLA Health, and M Health Fairview. This widespread adoption underscores the value and reliability of its technology in demanding clinical environments.
Nabla's platform, which handles 40 million patient encounters annually, integrates seamlessly with major EHRs like Epic and Oracle Cerner. A year ago, the company raised $70 million in a Series C round to fuel its expansion, and Manning's appointment signals a reinforced focus on the U.S. market. This strategic direction is further supported by the recent appointment of Laurie Soffiati to lead its French operations.
A Unified Vision for Clinical Intelligence
Looking ahead, Nabla is advancing its vision for Contextual Clinical Intelligence, aiming to create a unified AI layer that connects intelligence across the entire care journey. This initiative builds upon the company's leadership in ambient AI, dictation, and revenue cycle management. The goal is to move beyond fragmented AI tools toward a more intelligent and connected approach to healthcare delivery.
The founding team, including COO Delphine Groll and CTO Martin Raison, remains central to executing this vision and will continue to lead operations and technology. Groll noted that Manning aligns naturally with the company's customer-first mindset and ambition. This cohesive leadership team is poised to guide Nabla through its next stage of scaling and innovation.
Brian Manning's appointment as CEO marks a pivotal moment for Nabla, signaling a strategic acceleration of its commercial and market expansion efforts. With his extensive experience, a strong existing market footprint, and a clear technological vision, the company is well-positioned to solidify its leadership in the clinical AI sector. This new chapter promises to enhance Nabla's impact on reducing administrative burdens and improving care delivery for healthcare professionals worldwide.